Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.
Senior Associate, Seed Fund and Doctors Innovate Fund
Drew Wandzilak
Senior Associate, Green D and Yard and Strategic Tech Fund
Sarah Worden
Venture Scout
Ray Wu
Managing Partner-Web3 / Blockchain Fund
Michael Yuann
Director of Investment Operations
Past deals in Medical
TAU Systems
Seed Round in 2025
TAU Systems specializes in advanced medical imaging technology and the development of compact particle accelerators. The company has created innovative laser technology systems that significantly reduce the size of traditional particle accelerators from miles to meters. Their offerings include specialized x-ray free-electron lasers, which merge the functionality of large accelerators into a more manageable format. This technology provides vital beam-time access for various industries, facilitating advancements in nuclear, biotechnology, and medical research. By focusing on miniaturization and efficiency, TAU Systems aims to enhance the accessibility and utility of cutting-edge research methods.
Salvo Health
Seed Round in 2025
Salvo Health is a virtual health clinic that specializes in treating chronic gut conditions. The company enhances access to specialized healthcare for individuals suffering from these conditions through its app-based platform. Salvo Health utilizes a proprietary approach known as Whole Self Science, which considers various health factors beyond just gastrointestinal issues. This comprehensive model allows healthcare providers to identify the root causes of chronic illnesses and develop personalized, ongoing treatment strategies tailored to each patient's needs. By focusing on individualized care, Salvo Health aims to improve the overall well-being of those with chronic gut-related illnesses.
Springbok Analytics
Series A in 2025
Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.
Precision Neuroscience
Series C in 2024
Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.
MetaSight Diagnostics
Series A in 2024
MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).
Lōvu
Pre Seed Round in 2024
Lōvu Health is a digital health company specializing in maternal care. It provides a platform that supports mothers and babies from conception through to postpartum, using AI to deliver real-time analytics and evidence-based insights. The platform monitors vital signs like fetal heart rate and blood pressure, offers personalized recommendations, and sends action-oriented alerts, empowering users with reliable information and expert knowledge.
Canid
Series A in 2024
Canid is a company focused on enhancing the vaccination process for pediatricians by streamlining vaccination record management. Its innovative scanning system reduces the need for manual data entry, facilitating the automatic upload of vaccination information into state registries. The company's dashboard and process tools provide administrative consulting, ensure vaccine margins, automate workflow, and manage vaccine inventory. This comprehensive approach allows state officials and pediatric practitioners to concentrate on their core responsibilities, ultimately improving efficiency in vaccination administration.
Andromeda Surgical
Seed Round in 2024
Andromeda Surgical is a developer of autonomous robots designed to enhance the consistency, accuracy, and efficiency of surgical procedures. The company's open platform focuses on urologic procedures that have demonstrated superior outcomes but face challenges in widespread adoption due to technical complexities. By addressing these difficulties, Andromeda Surgical aims to empower surgeons to perform various procedures at a level typically achieved only by experts, thereby improving patient care and surgical success rates.
CytoVale
Series D in 2024
CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.
Centaur Labs
Series B in 2024
Centaur Labs specializes in medical data annotation services, aimed at enhancing medical decision-making and diagnostics. The company utilizes a platform that connects a global network of students and professionals, who compete to provide high-quality data labeling. This collaborative model ensures exceptional accuracy and scalability in annotating medical and scientific data. By analyzing medical cases and labeling data effectively, Centaur Labs contributes to the development of advanced medical AI technologies, ultimately helping patients achieve better healthcare outcomes while potentially reducing costs.
Bionic Health
Seed Round in 2024
Bionic Health is a digital healthcare company focused on providing preventative health services, particularly for individuals experiencing chronic pain. The company has developed a platform that utilizes frequent diagnostics and machine learning to create personalized treatment plans. This approach emphasizes slowing down the aging process and offers patients tailored insights derived from ongoing assessments. By implementing an iterative journey, Bionic Health enables users to identify their unique health needs and make impactful lifestyle changes over time. Additionally, patients benefit from closely monitored preventative care throughout the year, enhancing their overall well-being.
Syntra
Pre Seed Round in 2024
Syntra develops an EHR platform that streamlines billing, records, and follow-ups, helping doctors automate tasks.
GC Therapeutics
Series A in 2024
GC Therapeutics specializes in synthetic biology to efficiently program patient-derived stem cells into various cell types. The company has developed a proprietary platform that integrates synthetic biology and artificial intelligence, enabling streamlined manufacturing and improved quality of cell therapies. Their approach allows for the rapid differentiation of pluripotent stem cells, creating unique SuperCells™ customized for specific medical conditions. The foundational technology was developed in Professor George Church's lab at Harvard Medical School, and the team at GC Therapeutics comprises dedicated biologists and tissue engineers focused on translating this innovative method into practical therapies for patients.
InGel Therapeutics
Seed Round in 2024
InGel Therapeutics is a Cambridge, Massachusetts-based company founded in 2021 that focuses on developing stem cell therapeutics and biodegradable polymers. The company specializes in engineered cell therapy aimed at addressing neuroprotective pathways to treat retinal degeneration. By utilizing stem cells and their secretome, InGel Therapeutics seeks to provide neuroprotection for blinding diseases such as retinitis pigmentosa and macular degeneration. Their innovative approach involves using biodegradable polymers to isolate proteins of neuroprotective significance, first in vitro and subsequently in vivo, thereby enabling healthcare professionals to effectively treat patients suffering from retinal degeneration.
Hopscotch Primary Care
Series C in 2024
Operator of a data-driven healthcare startup intended to transform healthcare in rural communities through exceptional care, bringing better access and quality service to its patients. The company delivers tailored quality care through a team-based model, with resources and support for patients, inside and outside clinics, thereby enabling healthcare professionals to provide the support and care that patients need.
Grayce
Series A in 2024
Grayce, Inc. is a health care agency based in San Francisco that specializes in providing personalized support for families and employees managing the care of aging adults and children. Established in 2019, Grayce offers a comprehensive range of services, including assistance with insurance, finances, legal plans, medical care, home care, housing, and daily needs. The company emphasizes individualized guidance, ensuring that each member receives dedicated support from a social worker who helps manage their overall care. This includes planning, resource identification, care coordination, and advocacy, empowering family caregivers to effectively navigate the complexities of caring for their loved ones.
Bionaut Labs
Series B in 2024
Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.
ParcelBio
Seed Round in 2024
ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.
Nectero Medical
Series D in 2024
Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.
HelixNano
Series A in 2024
HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.
Pi Health
Series A in 2024
Pi Health is a technology company specializing in streamlining oncology clinical trials. It offers a global, secure, and compliant platform that integrates various systems, enabling life sciences companies to identify suitable trial sites, manage them efficiently, and accelerate the development of lifesaving medicines. This, in turn, enhances patient access to cancer care and research, particularly for diverse populations.
Nest Health
Seed Round in 2024
Nest Health is a family healthcare platform that provides a range of medical services aimed at reducing the stress associated with traditional healthcare arrangements. The company specializes in delivering in-home and virtual visits for patients of all ages, including newborns, children, teens, and adults. Their offerings encompass preventive care, sick visits, behavioral health support, nutrition guidance, and chronic disease management. By enabling patients to receive care in the comfort of their homes, Nest Health seeks to enhance accessibility and convenience in healthcare delivery.
BE Therapeutics
Seed Round in 2024
BE Therapeutics is a biotechnology company specializing in regenerative medicine. It develops innovative therapies aimed at repairing and restoring damaged brain and spinal cord tissue, focusing on engineering functional tissue to treat neurological conditions and spinal cord injuries.
Cyrus Biotechnology
Series B in 2024
Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.
Pendulum Therapeutics
Series C in 2024
Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.
Oula Health
Series B in 2024
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.
Piction Health
Seed Round in 2024
Piction Health is a dermatology care service that provides patients with rapid access to expert dermatological consultations for skin, hair, or nail concerns. Through its application, the company facilitates a streamlined process where patients receive a diagnosis and personalized care plan within two days. Piction Health employs artificial intelligence to enhance the experience for both patients and healthcare providers, enabling primary care physicians to obtain quick second opinions on complex skin conditions. This approach not only improves patient outcomes but also reduces unnecessary repeat visits and ineffective treatments, ultimately accelerating access to high-quality dermatology care from the comfort of home.
Granata Bio
Series A in 2024
Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.
DocStation
Seed Round in 2023
DocStation, Inc. is a cloud-based patient care platform designed for pharmacists, incorporated in 2017 and headquartered in Austin, Texas. The platform connects payers and pharmacists to facilitate value-based programs, aiming to reduce healthcare costs while enhancing patient outcomes. With over 500 providers collaborating with innovative health plans, DocStation equips pharmacists with tools that streamline patient management. Its comprehensive dashboard allows for the maintenance of current diagnoses, medications, immunizations, and allergies, while also facilitating the creation of care plans, monitoring adherence, and scheduling follow-ups. By enabling real-time connections between pharmacists and patients, DocStation supports a shift towards value-based care in the pharmacy sector.
CytoVale
Series C in 2023
CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.
Canid
Seed Round in 2023
Canid is a company focused on enhancing the vaccination process for pediatricians by streamlining vaccination record management. Its innovative scanning system reduces the need for manual data entry, facilitating the automatic upload of vaccination information into state registries. The company's dashboard and process tools provide administrative consulting, ensure vaccine margins, automate workflow, and manage vaccine inventory. This comprehensive approach allows state officials and pediatric practitioners to concentrate on their core responsibilities, ultimately improving efficiency in vaccination administration.
PulzAid
Pre Seed Round in 2023
PulzAid operates a managed marketplace focused on assisting injured workers in accessing a range of healthcare services, including telehealth, mobile imaging, and specialist consultations. By leveraging purpose-built software and established relationships with orthopedic surgeons and occupational medicine doctors, PulzAid aims to expedite treatment for employees, fostering quicker recovery and return to work. The company promotes a preventative approach to workplace injuries, offering services like on-demand video visits, in-person nurse visits, lab testing, and prescription services. This comprehensive model not only helps improve employee health outcomes but also assists employers in reducing costs associated with workplace injuries and workers' compensation claims.
Dentologie
Venture Round in 2023
Dentologie, founded by Dr. Hany Kurdi in 2013 and headquartered in Chicago, Illinois, aims to transform the dental experience by creating safe and inclusive environments for patients. The company specializes in urban dental solutions, providing a range of tech-enabled services that include general dentistry, Invisalign treatment, oral surgery, and cosmetic dentistry. Dentologie is committed to exceptional customer service and thoughtful design, ensuring that each patient receives personalized care and convenient access to dental solutions. By prioritizing compassion and competence, Dentologie seeks to change the perception of dental visits and enhance overall oral health.
Ossium Health
Series C in 2023
Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.
Upside Health
Seed Round in 2023
Upside Health, Inc. is a healthcare technology company based in New York, founded in 2017, that focuses on chronic pain management through its mobile application, Ouchie. This application provides targeted educational content and rewards for achieving functional milestones, fostering a support system for patients. Upside Health's platform includes remote patient monitoring and engagement tools that enable clinicians to enhance care quality while minimizing the burden on healthcare providers. By empowering patients with data and social support, Upside Health aims to improve outcomes for chronic pain sufferers and create revenue-generating opportunities for healthcare practices.
3X Genetics
Pre Seed Round in 2023
3X Genetics specializes in developing medical screening solutions aimed at identifying genetic disorders, particularly in infants and children. The company's technology focuses on screening for conditions such as myotonic dystrophy and other trinucleotide repeat disorders that lead to progressive muscle weakness. By offering these medical technologies, 3X Genetics enables healthcare professionals to proactively identify potential genetic issues, ultimately helping to prevent the birth of children affected by genetic diseases.
PharmaCCX
Seed Round in 2023
PharmaCCX, Inc. is a company that operates a market access platform designed to streamline the pricing and procurement of medicines for healthcare payers, thereby facilitating quicker patient access to necessary treatments. The platform primarily supports oncology pharmaceutical companies and various healthcare systems in the United States and Europe. Founded in 2017 and headquartered in Boston, Massachusetts, PharmaCCX also maintains offices in Stockholm, Sweden; San Mateo, California; and Zug, Switzerland. The company's software enhances the efficiency of market access teams within pharmaceutical companies and payers, enabling them to effectively plan, negotiate, and manage innovative payment models.
Mend
Series A in 2023
MEND is a life sciences company dedicated to advancing health and recovery through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that enhance patient outcomes in various contexts, including injury recovery, surgical recovery, aging, and physical performance. MEND's solutions have been widely adopted by hospitals, health systems, and professional sports teams across major leagues, as well as by the elite forces of the US Military. Through its commitment to ongoing research and development, MEND aims to empower caregivers and improve health outcomes for individuals facing diverse health challenges.
Pharmacy Mart
Seed Round in 2023
Pharmacy Mart is an online business-to-business marketplace established in 2021 and based in Cairo, Egypt. The platform facilitates pharmacists in obtaining daily prescriptions and medications from various suppliers, allowing them to access a wide range of pharmacy supplies efficiently. By integrating fintech and logistics, Pharmacy Mart provides a user-friendly interface where medical suppliers can list their products, enabling pharmacists to find suitable offers for their daily supply needs. The service also includes discounts and eliminates delivery charges, making it a cost-effective solution for pharmacy operations.
DropStat
Venture Round in 2023
DropStat is a technology company that offers an app-based platform designed to optimize staffing for hospitals. Founded in 2017 and headquartered in Beverly Hills, California, DropStat utilizes artificial intelligence and machine learning to predict and autonomously fill staffing gaps, allowing healthcare facilities to manage labor costs more effectively. By streamlining the process of calling staff for open shifts, the platform eliminates the need for traditional communication methods such as calls and texts, thereby enhancing efficiency and reducing financial waste. In addition to improving operational processes, DropStat prioritizes data security, ensuring that sensitive information is protected both in the system and during transmission. The company's mission is to modernize shift communication, ultimately aiming to enhance both patient and staff satisfaction.
Pathfinder Health
Seed Round in 2023
Pathfinder Health is focused on enhancing child development for children aged 0-5 through its evidence-based clinical tool. This pediatric application aids parents and caregivers in monitoring developmental milestones, encouraging cognitive, physical, social, emotional, and communication growth through play. It facilitates communication with healthcare providers, allowing for earlier diagnoses of potential developmental issues. The app offers step-by-step guidance tailored to a child's current stage of development and connects users to additional resources, including developmental activities, articles, parenting tips, and local early intervention services. By providing these tools, Pathfinder Health empowers families to track their child's progress and seek timely intervention when necessary.
Andromeda Surgical
Seed Round in 2023
Andromeda Surgical is a developer of autonomous robots designed to enhance the consistency, accuracy, and efficiency of surgical procedures. The company's open platform focuses on urologic procedures that have demonstrated superior outcomes but face challenges in widespread adoption due to technical complexities. By addressing these difficulties, Andromeda Surgical aims to empower surgeons to perform various procedures at a level typically achieved only by experts, thereby improving patient care and surgical success rates.
Mign
Seed Round in 2023
Mign specializes in developing personalized medical devices for musculoskeletal health, focusing on digitally tailored orthopedic products. The company employs proprietary technology that transforms complex three-dimensional body data into customized wearable items. These products feature breathable three-dimensional patterns designed to meet individual physical needs, effectively addressing various orthopedic issues. Mign aims to revolutionize the design, engineering, manufacturing, and delivery processes of medical devices, contributing to a more digital and sustainable future in healthcare.
Bionic Health
Seed Round in 2023
Bionic Health is a digital healthcare company focused on providing preventative health services, particularly for individuals experiencing chronic pain. The company has developed a platform that utilizes frequent diagnostics and machine learning to create personalized treatment plans. This approach emphasizes slowing down the aging process and offers patients tailored insights derived from ongoing assessments. By implementing an iterative journey, Bionic Health enables users to identify their unique health needs and make impactful lifestyle changes over time. Additionally, patients benefit from closely monitored preventative care throughout the year, enhancing their overall well-being.
Dimension Inx
Series A in 2023
Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.
Precision Neuroscience
Series B in 2023
Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.
Oula Health
Series A in 2023
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.
Gilgamesh Pharmaceuticals
Series B in 2022
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
Axoft
Seed Round in 2022
Axoft is a company focused on developing advanced implantable electronics that enhance communication between the brain and machines. Its flagship technology consists of bioinspired implants made from ultra-flexible plastic mesh, which provides a softer alternative to traditional plastic and silicone implants. This innovative design allows for scalability and the integration of multiple sensors within a single implant, closely matching the brain's mechanical properties. Axoft's implants aim to improve clinical outcomes for patients suffering from neurodegenerative conditions, such as Parkinson's disease, thereby transforming individual health and overall human experience.
SURGE Therapeutics
Series A in 2022
SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.
Brave Health
Series C in 2022
Brave Health operates a virtual clinic that provides telehealth services focused on mental health and addiction treatment. Established in 2017 in Miami, Florida, the company specializes in behavioral health, offering a range of services including counseling, therapy, psychiatry, and medication management, which encompasses medication-assisted treatment. This telehealth approach allows patients to receive comprehensive care for various conditions related to mental health and substance use disorders, facilitating greater access to necessary treatment.
Koala Health
Series A in 2022
Koala Health is a Boston-based company founded in 2021 that specializes in providing medications and health products for pets. The company simplifies pet care by verifying and fetching prescriptions from veterinarians, sorting and packaging medications by date and time, and offering free delivery and refills. By focusing on vet-approved medications and supplements, Koala Health aims to enhance the quality of life for pets and support pet owners in managing their pets' health needs effectively.
PathSpot
Series A in 2022
PathSpot Technologies, Inc., established in 2017 and headquartered in New York City, specializes in food safety solutions. The company develops and manufactures a unique system that uses a proprietary algorithm to analyze fluorescent light, enabling it to scan employees' hands and detect pathogens that cause food-borne illnesses. This technology helps restaurants and their customers mitigate the risk of food-borne illnesses by providing instant, invisible signs of harmful bacteria and viruses.
Remedial Health
Seed Round in 2022
Remedial Health operates as a wholesale distributor of medicine, catering to the vast network of approximately one million pharmacies and hospitals across Africa. The company addresses the prevalent inefficiencies in the healthcare supply chain, where providers often depend on open-air markets to acquire pharmaceuticals, leading to risks of counterfeit products. By offering a pharmacy operations and procurement management platform, Remedial Health enhances business-to-business access to medications. This platform incorporates technology that simplifies the ordering process and facilitates direct access to retail medicines from manufacturers or distributors, thereby improving workflow management and ensuring a more reliable supply of genuine medications for healthcare providers.
Nanopath
Series A in 2022
Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.
Moving Analytics
Series A in 2022
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.
Swing Therapeutics
Series A in 2022
Swing Therapeutics focuses on developing innovative digital therapeutics aimed at helping individuals with chronic conditions. The company collaborates with leading researchers to create evidence-based treatments that enhance patient empowerment and control over their health. By offering novel prescription digital therapeutics, Swing supports patients in managing their illnesses more effectively, ultimately fostering improved health outcomes and promoting a more vibrant quality of life.
Boulder Care
Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.
Pharmacy Mart
Seed Round in 2022
Pharmacy Mart is an online business-to-business marketplace established in 2021 and based in Cairo, Egypt. The platform facilitates pharmacists in obtaining daily prescriptions and medications from various suppliers, allowing them to access a wide range of pharmacy supplies efficiently. By integrating fintech and logistics, Pharmacy Mart provides a user-friendly interface where medical suppliers can list their products, enabling pharmacists to find suitable offers for their daily supply needs. The service also includes discounts and eliminates delivery charges, making it a cost-effective solution for pharmacy operations.
NeuraLight
Series A in 2022
NeuraLight is a venture-backed company focused on improving the lives of individuals affected by neurological disorders through digital solutions. The company has developed a digital neurology platform that utilizes a proprietary, de-identified oculometric database. This technology allows for the analysis of eye movement using standard smartphones or webcams, enabling clinicians to effectively differentiate between patients and healthy individuals, categorize various subgroups, and track disease progression. By digitizing evaluation and care, NeuraLight aims to enhance diagnostic accuracy and treatment for those impacted by neurological conditions.
Legacy
Series B in 2022
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
American Gene Technologies
Series D in 2022
American Gene Technologies International Inc., established in 2007 and based in Rockville, Maryland, is a biotechnology company specializing in gene and cell therapeutics. It develops a lentiviral platform with broad applications, including large and orphan indications, infectious diseases, immuno-oncology, and monogenic disorders. The company's portfolio includes a lead candidate for an HIV functional cure, a novel immuno-oncology approach to stimulate gamma-delta T cells, and a synthetic gene for treating Phenylketonuria (PKU). AGT aims to create long-term value for patients, society, and investors by developing and testing cutting-edge gene therapies to cure some of humanity's worst diseases.
Satellite Bio
Series A in 2022
Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.
Curbside Health
Seed Round in 2022
Curbside Health develops clinical decision support software that aligns health systems and clinicians to more efficiently deliver optimal care. The company was founded by physicians and technologists to combine the best of clinical evidence with the realities of healthcare delivery and with opportunities of modern web technology. We support health systems and hospitals to expand their clinical content library (e.g. clinical pathways, protocols, guidelines, A3s, checklists, etc) and enhance the utilization of these resources at the point-of-care. Together, the components of Curbside's platform enable a hospital to improve clinical outcomes and operational efficiencies. Product development is informed by working closely with patients, clinicians, engineers, physicians, healthcare administrators, and payors. Our mission is hiding in plain sight within our name, and those in healthcare will understand: every medical decision is informed in real-time by the world's expert of that particular situation, while simultaneously accounting for hospital policy and all relevant patient-specific data. Essentially, Curbside is on a never-ending quest to perfect medical decision making.
Iterative Scopes
Series B in 2022
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and the life sciences sector, particularly in the areas of colorectal cancer and inflammatory bowel disease. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical health areas.
Hey Jane
Seed Round in 2022
Hey Jane is a telehealth startup that connects patients to healthcare providers that offer online medical consultations. The company's innovative Complete Care model utilizes technology for unparalleled layers of support: medical, emotional, and social. Since 2021, Hey Jane has helped nearly 20,000 patients get the care they need. And this is only the beginning; soon, we will reimagine care for even more common but underserved treatments, with the ultimate goal of becoming the most trusted healthcare company out there—one that pushes the boundaries of access with convenient, inclusive, and patient-driven care.
Luma Health
Series C in 2021
Luma Health Inc. is a San Francisco-based company that specializes in developing a patient engagement platform aimed at enhancing the connection between healthcare providers and patients. Founded in 2015, the platform facilitates smart scheduling and referral management while offering features such as appointment reminders, mobile patient intake, and care pathways. It enables healthcare systems and clinics to keep their schedules full and supports patient adherence to care plans. Additionally, Luma Health provides tools for patient communication and analytics, ensuring that healthcare providers can deliver continuous care and improve treatment outcomes. The company emphasizes a modern, mobile-first approach to patient engagement.
Transcend Therapeutics
Series A in 2021
Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company aims to create psychoactive medicines targeting specific brain regions involved in neuropsychiatric disorders. By doing so, Transcend Therapeutics seeks to enable healthcare professionals to facilitate positive changes in brain function and behavior for patients suffering from these conditions.
Gordy Health
Convertible Note in 2021
Gordy Health is a virtual care provider specializing in blood pressure management to reduce the risk of serious health complications such as heart attacks, strokes, and kidney failure. Founded in 2021 and headquartered in Pasadena, California, the company offers a healthcare platform that allows users to manage their blood pressure from home. This platform provides direct access to heart specialists, facilitates easy scheduling of virtual appointments, and includes features such as real-time diagnostics, prescription delivery, and continuous monitoring and medication adjustments. By focusing on proactive management of high blood pressure, Gordy Health aims to help individuals lead healthier lives and extend their longevity.
Evernow
Convertible Note in 2021
Evernow is a provider of women's health care services focused on supporting women before, during, and after menopause. The company offers an online teleconsultation platform that connects users with specialized doctors and provides access to science-backed information and treatments. Through this platform, Evernow facilitates conversations about effective care for managing changing hormones, empowering women to lead longer and healthier lives.
GritWell
Seed Round in 2021
GritWell Ltd is a digital health platform established in 2018, based in San Francisco, California. The company focuses on addressing chronic health conditions by shifting the emphasis from symptom management to identifying and treating root causes. GritWell connects patients suffering from various chronic symptoms, such as insomnia, migraines, digestive issues, anxiety, and joint pain, with nutritionists, health coaches, and holistic practitioners. Its platform offers personalized care through clinically validated symptom assessments and facilitates secure video consultations, direct messaging, and an online portal for scheduling and managing patient records. By integrating natural treatments and providing tailored treatment plans, GritWell aims to enhance patient outcomes and support a holistic approach to health.
Blue Note Therapeutics
Series A in 2021
Blue Note Therapeutics is a prescription digital therapeutics company based in San Francisco, California, founded in 2018. The company focuses on enhancing mental health care for cancer patients through its innovative digital therapeutics platform. By collaborating with medical researchers and patient advocacy organizations, Blue Note Therapeutics delivers evidence-based therapeutic interventions via mobile devices. This approach allows patients to access effective treatments designed to prevent, manage, and address their medical conditions, enabling healthcare providers to utilize these digital solutions as primary or supplementary therapies for serious illnesses.
AdaptX
Series A in 2021
AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.
Sorcero
Venture Round in 2021
Sorcero, Inc. is a technology company based in Washington, D.C., founded in 2017, that specializes in developing a no-code, AI-powered platform designed for decision support and knowledge management. The Sorcero Language Intelligence Platform caters primarily to experts in medical, insurance, and engineering fields, enabling them to manage and analyze complex, high-volume data effectively. This platform is utilized for various applications, including enhancing medical claims investigations, supporting life insurance underwriting, and monitoring real-time medical guidelines. Sorcero's innovative approach has earned it recognition as a leader in the digital health and insurtech sectors, receiving accolades from industry organizations for its contributions to improving patient outcomes and decision-making processes in life sciences.
Cyrus Biotechnology
Venture Round in 2021
Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.
SHINE Technologies
Series C in 2021
SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.
miRecule
Venture Round in 2021
miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.
Future Family
Series A in 2021
Future Family, Inc. is a subscription-based fertility company founded in 2016 and headquartered in San Francisco, California. It provides comprehensive healthcare solutions for individuals and couples navigating fertility challenges, offering plans that cover all associated costs. The company's services include personalized fertility planning, clinic matching, and a dedicated nurse concierge, ensuring 24/7 access to a care team. Future Family specializes in on-demand medical support for procedures such as in vitro fertilization (IVF) and egg freezing, and it features a digital health platform for managing fertility care. By combining financial assistance with expert guidance, Future Family aims to deliver a stress-free fertility experience for its clients.
Gilgamesh Pharmaceuticals
Series A in 2021
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
Intus Care
Seed Round in 2021
Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.
PulseData AI
Series A in 2021
PulseData AI, established in 2015 and headquartered in New York, specializes in healthcare technology. It develops machine learning software that helps healthcare providers identify patients at high risk of adverse, preventable medical outcomes. The company's platform analyzes vast amounts of patient data to predict health trends, enabling care management teams to deliver timely, targeted interventions and improve overall patient outcomes.
KLOWEN Braces
Seed Round in 2021
KLOWEN Braces, Inc. is a company based in Fort Collins, Colorado, that specializes in developing custom braces systems for orthodontists and their patients. Founded in 2019, KLOWEN Braces utilizes a software platform to create ideally shaped brackets for each tooth, enhancing the effectiveness and comfort of the orthodontic treatment. The company offers a range of products, including prefabricated, modular brackets, as well as brackets with hooks, bundles, tubes, and wires, available for online purchase. By combining innovative technology with quality materials, KLOWEN aims to provide a faster and more comfortable alternative to traditional braces.
Scipher Medicine
Series C in 2021
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
InteRNA Technologies
Series B in 2021
InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.
Conversa Health
Series B in 2021
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.
Centivo
Series B in 2020
Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.
STIMIT
Venture Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Shoulder Innovations
Venture Round in 2020
Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed a Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical challenge of reliable fixation for glenoid implants. This technology not only enhances post-surgical implant stability, reducing the risk of revision surgeries, but also simplifies surgical instrumentation, which can lead to shorter operative times and lower costs. Shoulder Innovations markets its products through distribution partners across the United States, aiming to improve patient care and reduce overall healthcare costs.
Small Door
Seed Round in 2020
Small Door, Inc., founded in 2017 and headquartered in New York City, provides veterinary services characterized by a focus on customer experience and convenience. The company emphasizes elevated care, transparency, and a hospitality-oriented approach, aiming to enhance the lives of both pets and their owners. Operating 13 veterinary practices across New York City, Boston, and Washington, D.C., Small Door has facilitated tens of thousands of consultations for its members, showcasing its commitment to exceptional service in the veterinary industry.
SHINE Technologies
Venture Round in 2020
SHINE Technologies, LLC is a medical technology company that specializes in the production and supply of medical tracers and cancer treatment elements. It primarily manufactures and distributes molybdenum-99 (moly-99), a key isotope used in the diagnosis and staging of various diseases, including cancer and heart disease. Additionally, SHINE offers iodine-131 and iodine-125 for treating thyroid cancer and other abnormal thyroid conditions, as well as for diagnosing liver function, kidney blood flow, and urinary tract obstruction. The company also provides xenon-133 for evaluating lung function and blood flow, particularly in the brain. SHINE's products are used extensively in the United States and internationally. Founded in 2010, the company is headquartered in Janesville, Wisconsin, with an additional office in Alkmaar, the Netherlands.
Brio
Seed Round in 2020
Brio Systems, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in COVID-19 testing solutions for workplaces. Its comprehensive platform offers on-site PCR and antibody testing, logistical support, medical oversight, and digital results communication within three days. Brio connects employers with a network of FDA-certified labs, serving industries such as manufacturing and food processing. The company's secure platform also provides diagnostic testing services for individuals, focusing on blood metrics like sugar and hormone levels, offered on a monthly subscription basis.
Conversa Health
Venture Round in 2020
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.
Conversa Health
Series B in 2020
Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.
Better Life Partners
Series A in 2020
Better Life Partners Inc. is a healthcare provider based in Hanover, New Hampshire, focused on supporting individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners utilizes technology to create personalized care plans that adapt to clients' needs, ensuring effective healthcare delivery through telehealth and community-based solutions. By integrating medical and behavioral healthcare, the company aims to address the complex needs of patients, providing comprehensive support to help them recover from addiction. Better Life Partners has additional offices across various locations in New Hampshire, reflecting its commitment to serving vulnerable populations.
Grayce
Seed Round in 2020
Grayce, Inc. is a health care agency based in San Francisco that specializes in providing personalized support for families and employees managing the care of aging adults and children. Established in 2019, Grayce offers a comprehensive range of services, including assistance with insurance, finances, legal plans, medical care, home care, housing, and daily needs. The company emphasizes individualized guidance, ensuring that each member receives dedicated support from a social worker who helps manage their overall care. This includes planning, resource identification, care coordination, and advocacy, empowering family caregivers to effectively navigate the complexities of caring for their loved ones.
Brio
Venture Round in 2020
Brio Systems, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in COVID-19 testing solutions for workplaces. Its comprehensive platform offers on-site PCR and antibody testing, logistical support, medical oversight, and digital results communication within three days. Brio connects employers with a network of FDA-certified labs, serving industries such as manufacturing and food processing. The company's secure platform also provides diagnostic testing services for individuals, focusing on blood metrics like sugar and hormone levels, offered on a monthly subscription basis.
Mission Bio
Venture Round in 2020
Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Emulate
Series D in 2020
Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.
Emulate
Debt Financing in 2020
Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.
Matchwell
Venture Round in 2020
Matchwell LLC is an online marketplace that connects healthcare professionals, such as nurses and therapists, with healthcare facilities seeking staff. Founded in 2017 and headquartered in Durham, North Carolina, Matchwell allows clinicians to join preferred facility pools, view available shifts, and communicate directly with hiring managers. The platform caters to both short-term and long-term employment needs, promoting flexibility in work arrangements. By leveraging technology and artificial intelligence, Matchwell aims to enhance workforce management for healthcare organizations while providing transparency and direct access to job opportunities for clinicians. With over 50,000 clinicians and 1,000 healthcare sites under contract, Matchwell is actively redefining the dynamics of a flexible healthcare workforce.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.